present
case
girl
renal
cardiac
manifest
atyp
haemolyt
uraem
syndrom
ahu
novel
complement
factor
h
mutat
transient
haematolog
remiss
achiev
intens
plasmapheresi
cardiac
function
deterior
renal
function
restor
initi
eculizumab
month
dialysi
significantli
improv
organ
function
month
present
haematolog
valu
normalis
cardiac
function
improv
dialysi
discontinu
month
longest
report
time
patient
ahu
estim
glomerular
filtrat
rate
recov
mlmin
conclus
treatment
ahu
eculizumab
even
longterm
dialysi
significantli
improv
renal
function
discontinu
dialysi
resolut
cardiac
function
implic
potenti
recoveri
treatment
choic
patient
earlier
initi
eculizumab
howev
might
prevent
irrevers
renal
sclerosi
cardiac
dysfunct
atyp
haemolyt
uraem
syndrom
ahu
rare
diseas
mainli
associ
uncontrol
complement
activ
lead
endotheli
cell
damag
develop
system
thrombot
microangiopathi
tma
clinic
ahu
characteris
coombsneg
anaemia
thrombocytopenia
organ
dysfunct
frequent
manifest
ahu
kidney
damag
cardiac
complic
occur
patient
due
system
natur
tma
recent
plasma
exchangeplasma
infus
pepi
option
manag
patient
ahu
key
treatment
advanc
avail
eculizumab
humanis
monoclon
antibodi
licens
usa
eu
russia
studi
date
eculizumab
demonstr
high
efficaci
children
adult
ahu
achiev
remiss
haematolog
symptom
improv
case
full
recoveri
renal
function
unclear
howev
whether
benefit
continu
prevent
tma
eculizumab
patient
treatment
immedi
initi
longterm
tma
caus
signific
injuri
organ
review
relev
literatur
present
illustr
case
studi
girl
present
day
polio
vaccin
repeat
vomit
fever
stool
chang
patient
admit
hospit
day
initi
investig
reveal
peripher
oedema
arteri
hypertens
mm
hg
anaemia
haemoglobin
hb
gdl
thrombocytopenia
platelet
l
renal
failur
decreas
urin
output
mlkgh
creatinin
urea
mmoll
proteinuria
gl
indic
tma
organ
damag
test
confirm
tma
blood
film
schistocyt
renal
biopsi
elimin
immunemedi
diseas
direct
indirect
coomb
test
conduct
child
present
classic
featur
tma
renal
failur
without
prior
relev
medic
histori
common
caus
would
shiga
toxinproduc
escherichia
coli
stec
haemolyt
urem
syndrom
hu
howev
rarer
atyp
form
hu
thrombot
thrombocytopen
purpura
ttp
also
consid
patient
diarrhoea
gastrointestin
infect
preced
tma
test
shiga
toxin
hiv
streptococcu
pneumonia
neg
ttp
rule
adamt
disintegrin
metalloproteinas
thrombospondin
type
motif
activ
normal
stechu
ahu
ttp
would
differ
treatment
modal
optim
outcom
thu
differenti
diagnosi
import
earli
stage
rare
caus
membranoprolif
glomerulonephr
dens
deposit
diseas
glomerulonephr
rule
immunofluoresc
stain
renal
biopsi
reveal
neither
immunoglobulin
igg
iga
igm
deposit
data
shown
although
complement
protein
may
normal
approxim
patient
ahu
plasma
level
may
normal
paediatr
patient
due
local
rather
system
consumpt
low
howev
suggest
aberr
fluid
phase
complement
regul
patient
low
level
mgdl
posit
complement
haemolysi
ch
test
despit
initi
complement
factor
h
cfh
level
within
normal
rang
renal
biopsi
histolog
week
present
also
consist
tma
figur
test
cobalamin
c
defici
import
differenti
diagnosi
children
avail
time
diagnosi
ahu
made
base
clinic
present
evid
complement
consumpt
genet
screen
complement
mutat
implic
immedi
patient
manag
inform
longterm
treatment
decis
patient
genet
screen
result
obtain
year
initi
present
identifi
heterozyg
mutat
cfh
exon
well
heterozyg
polymorph
gene
g
initi
avail
manag
strategi
fresh
frozen
pi
loop
diuret
anticoagul
therapi
heparin
uday
platelet
antiaggreg
therapi
dipyridamol
mgday
prednisolon
mgkg
also
prescrib
patient
improv
first
month
diuresi
increas
approxim
mlday
howev
diuresi
soon
decreas
mlday
day
blood
pressur
suddenli
increas
mm
hg
hb
decreas
although
platelet
count
normal
l
patient
transfer
children
clinic
hospit
st
vladimir
moscow
receiv
pe
month
initi
present
patient
remain
anaem
hb
gdl
thrombocytopen
platelet
l
increas
creatinin
lactat
dehydrogenas
ldh
ul
despit
continu
venoven
haemodiafiltr
periton
dialysi
regular
pe
tma
manifest
occur
subsequ
develop
cardiomyopathi
eject
fraction
requir
digitali
treatment
sever
hypertens
mm
hg
persist
eculizumab
mg
everi
day
initi
month
diseas
onset
vaccin
mening
haemophilu
influenza
type
b
pneumococc
infect
patient
prophylact
antibiot
local
practic
month
eculizumab
therapi
pe
requir
urin
output
increas
mlday
hypertens
less
pronounc
mm
hg
control
calciumchannel
blocker
four
month
start
eculizumab
periton
dialysi
discontinu
day
anuria
month
dialysi
figur
recent
followup
visit
hb
gdl
ldh
ul
platelet
count
l
creatinin
mmoll
urea
mmoll
within
near
normal
rang
level
remain
low
mgdl
normal
mgdl
complement
activ
absent
ch
lysi
renal
test
show
daili
urinari
protein
mg
estim
glomerular
filtrat
rate
egfr
kidney
doppler
ultrasound
may
show
irrevers
damag
sclerosi
reduc
arteri
blood
flow
ischaemia
cortic
parenchyma
echocardiographi
reveal
small
left
ventricl
dilat
improv
eject
fraction
global
leftventricular
myocardi
contractil
reduc
myocardi
hypertrophi
resolv
sinc
present
ahu
patient
undergon
rapid
growth
weight
gain
improv
appetit
normalis
sleep
pattern
eculizumab
well
toler
eculizumab
treatment
child
two
sever
acut
respiratori
syndrom
episod
acut
intestin
infect
focal
pneumonia
chicken
pox
infect
lead
clinic
manifest
tma
despit
delay
administr
eculizumab
day
figur
base
ch
measur
complement
blockad
maintain
throughout
patient
ahu
rapidli
develop
endstag
renal
diseas
esrd
within
first
year
present
tma
process
rapidli
inhibit
unclear
howev
patient
alreadi
esrd
sever
month
possibl
renal
recoveri
whether
risk
diseas
progress
one
initi
clinic
trial
eculizumab
conduct
patient
ahu
chronic
kidney
diseas
despit
longterm
therapi
pe
two
patient
receiv
longterm
dialysi
day
respect
dialysi
could
discontinu
eculizumab
initi
second
trial
patient
recent
progress
tma
four
five
patient
receiv
dialysi
rang
day
abl
discontinu
dialysi
longterm
eculizumab
treatment
knowledg
longest
report
durat
dialysi
eculizumab
treatment
permit
dialysi
discontinu
month
girl
ahu
result
cfh
mutat
also
woman
ahu
discontinu
dialysi
month
result
eculizumab
treatment
convers
report
patient
renal
damag
advanc
recov
eculizumab
treatment
even
though
prior
dialysi
durat
shorter
month
initi
manag
standard
therapi
pi
anticoagul
steroid
associ
improv
symptom
howev
month
post
present
patient
deterior
seven
month
pe
result
clinic
benefit
eculizumab
initi
led
discontinu
dialysi
patient
month
anuria
notabl
longterm
eculizumab
may
allow
recoveri
repair
renal
tissu
even
patient
longterm
diseas
clinic
studi
patient
egfr
increas
mean
mlmin
month
eculizumab
treatment
maintain
year
mean
improv
renal
function
patient
normalis
egfr
improv
month
eculizumab
treatment
renal
biopsi
reveal
characterist
prior
tma
sclerosi
ischaemia
renal
tissu
furthermor
eculizumab
also
improv
patient
critic
hypertens
myocardi
hypertrophi
patient
eculizumab
treatment
delay
drug
approv
russia
earlier
treatment
might
prevent
sever
irrevers
kidney
damag
also
develop
cardiovascular
complic
complementmedi
vascular
injuri
progress
tma
occur
despit
normal
haematolog
valu
lack
overt
tma
manifest
extraren
tma
figur
haematolog
renal
paramet
pepi
eculizumab
treatment
xaxi
repres
time
week
sinc
present
dash
horizont
line
show
lower
limit
normal
platelet
haemoglobin
upper
limit
normal
ldh
creatinin
egfr
measur
week
present
patient
anur
egfr
estim
glomerular
filtrat
rate
ldh
lactat
dehydrogenas
pe
pi
plasma
exchangeplasma
infus
manifest
develop
patient
haematolog
remiss
around
patient
ahu
extraren
tma
progress
tma
previous
report
anephr
patient
eculizumab
treatment
led
resolut
patient
cardiomyopathi
extraren
complic
often
consid
relat
ahu
highlight
valu
continu
blockad
complement
fact
level
remain
low
patient
despit
eculizumab
treatment
may
indic
presenc
nephrit
factor
autoantibodi
stabilis
convertas
continu
upstream
complement
consumpt
histolog
examin
demonstr
involv
upstream
complement
activ
inhibit
eculizumab
bind
despit
continu
low
level
eculizumab
inhibit
downstream
complement
pathway
activ
diseas
progress
absenc
thrombocytopenia
show
valid
clinic
biomark
confirm
diagnosi
ahu
monitor
eculizumab
treatment
requir
discord
find
individu
biomark
includ
ch
document
ex
vivo
assay
monitor
complement
deposit
endotheli
cell
may
prove
effect
monitor
eculizumab
effici
personalis
eculizumab
therapi
recent
key
role
mutat
polymorph
complement
factor
gene
establish
ahu
patient
ahu
occur
due
complement
activ
condit
vaccin
multipl
genet
risk
factor
mutat
polymorph
cfh
posit
cfh
mutat
import
bind
regul
altern
complement
pathway
activ
endotheli
cell
associ
ahu
diseas
phenotyp
howev
amino
acid
chang
cy
tyr
previous
report
includ
nation
heart
lung
blood
institut
exom
sequenc
project
http
evsgswashingtoneduev
substitut
affect
disulphid
bond
http
conserv
amino
acid
cterminu
cfh
moreov
chang
predict
potenti
pathogen
mutat
analysi
softwar
sort
intoler
toler
sift
score
deleteri
chang
http
siftjcviorg
score
probabl
damag
http
geneticsbwhharvard
fact
patient
manifest
tma
despit
multipl
infect
complement
activ
condit
treatment
eculizumab
indic
dose
utilis
adequ
block
termin
complement
product
case
knowledg
longest
report
time
patient
ahu
chronic
dialysi
success
discontinu
dialysi
despit
clinic
evid
neither
thrombocytopenia
haemolysi
extraren
manifest
progress
time
may
repres
subclin
complementmedi
inflammatori
respons
lead
thrombosi
coronari
arteriol
capillari
correspond
ischaem
heart
damag
dysfunct
case
also
demonstr
potenti
recoveri
renal
organ
function
eculizumab
treatment
child
ahu
despit
delay
initi
treatment
confirm
ahu
identif
genet
mutat
cfh
suggest
lifelong
eculizumab
treatment
necessarywithdraw
therapi
risk
inappropri
altern
complement
cascad
activ
associ
lifethreaten
complic
numer
precipit
factor
thank
treatment
daughter
receiv
recov
seriou
ill
feel
good
goe
school
develop
normal
age
wish
treatment
continu
longterm
understand
caus
genet
explain
us
without
treatment
diseas
could
recur
time
eculizumab
treatment
enabl
patient
atyp
haemolyt
uraem
syndrom
ahu
discontinu
dialysi
month
anuria
resolut
cardiac
complic
often
consid
relat
ahu
suggest
continu
eculizumab
treatment
justifi
extraren
complic
ahu
may
progress
despit
overt
thrombocytopenia
haemolysi
highlight
import
continu
treatment
need
reliabl
diseas
biomark
eculizumab
led
improv
function
kidney
organ
despit
delay
initi
treatment
contributor
ke
et
respons
treatment
cours
patient
data
collect
ev
bvdh
perform
genet
analysi
interpret
ke
et
help
interpret
data
draft
manuscript
author
provid
critic
revis
content
read
approv
final
manuscript
